Conference Edition
| June 28, 2019
|
Clinical trials can significantly accelerate research, leading to better outcomes for patients, sites, and sponsors.
Here's what you need to know >>
Brought to you by
|
Editor's Note
If two words described this year's Drug Information Association annual conference, Barbara Kunz, its global chief executive, says they would be "digital" and "patient." I'd say she's on the mark.
On the sprawling exhibit floor of the San Diego Convention Center, vendors tried to show why they were at the forefront of both. Panels about incorporating devices into clinical trials or designing studies for niche populations were some of the most heavily attended.
Regulators joined in as well. One conference attendee noted how an FDA reviewer came up to ask her how the agency was doing in the emerging technology space. That didn't used to happen.
Still, there's much to improve. In clinical trials, too often the patient experience is either on the backburner or ignored entirely. And in drug pricing transparency, hospital payments methods are still frustratingly opaque.
Below, you'll find stories covering the biggest trends, challenges and questions presented at DIA 2019. Want to add to the conversation? My inbox is always open. As always, thanks for reading.
Jacob
Bell
Reporter, BioPharma Dive
E-mail
Overheard at the show
"You still see in this building a lot of niche CROs doing specialized services. Where are the midsize CROs? There's no market for them anymore."
– Dawn Anderson, managing director of Deloitte R&D life sciences consulting
Event coverage
Deep Dive
Drugmakers and regulators are paying more attention to what real-world data can prove — driving demand for CROs to help keep up.
Read More »
|
Q&A
Barbara Kunz, DIA's global chief executive, noted that when it comes to new technology, "there's a pretty big mountain that we'll be climbing. Some of the early successes will seem trivial a year from now."
Read More »
|
Eliminate the delays and/or inaccuracies associated with accruing for grant payments in financials, while improving site relations by paying on time.
|
The information is viewed as a valuable tool for improving trial design, guiding drug approvals and supporting label decisions, but its reach has been limited.
Read More »
|
The payment model, often opaque on specific drug costs, affects many of the medicines the hospital-led group is targeting, according to its commercial chief.
Read More »
|
Parting thought
Long a buzzword, "patient centricity" is now becoming standard practice. Regulators, drugmakers and vendors risk looking antiquated — and losing valuable data — if clinical trials don't consult patients on their experiences.
|
